Gilead Sciences Inc

GILD

Company Profile

  • Business description

    Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

  • Contact

    333 Lakeside Drive
    Foster CityCA94404
    USA

    T: +1 650 574-3000

    E: [email protected]

    https://www.gilead.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    17,600

Gilead Sciences Inc News & Analysis

stocks

10 cheap wide-moat US stocks for 2025

Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
personal-finance

US stock market outlook: tariffs are 2025's wild card

Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks

10 cheap US dividend-growth stocks to buy

The stocks of these companies with a history of dividend increases look undervalued today.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,088.2059.400.66%
CAC 407,621.0410.97-0.14%
DAX 4023,846.0788.380.37%
Dow JONES (US)44,111.7461.90-0.14%
FTSE 1009,142.7314.430.16%
HKSE24,902.53169.080.68%
NASDAQ20,916.55137.03-0.65%
Nikkei 22540,529.1220.42-0.05%
NZX 50 Index12,905.1228.080.22%
S&P 5006,299.1930.75-0.49%
S&P/ASX 2008,823.5053.100.61%
SSE Composite Index3,617.6034.290.96%

Market Movers